Psilocybin-assisted Therapy for Alcohol Use Disorder

This double-blind, randomised, Phase II trial (n=90) will evaluate the efficacy of psilocybin-assisted therapy (25mg) for reducing alcohol consumption in individuals with Alcohol Use Disorder (AUD).

Conducted by the University of Sydney, the study compares the effects of psilocybin (25mg) combined with psychotherapy against a control treatment of niacin (250mg) and psychotherapy. Over a 14-week period, participants will receive 12 therapy sessions and two dosing sessions with either psilocybin or niacin.

The primary outcome is the frequency of heavy drinking days, while secondary outcomes include overall alcohol consumption, anxiety, depression, and quality of life.

The trial aims to assess the potential of psilocybin to improve drinking patterns and psychological well-being in individuals with AUD.

Topic Alcohol Use Disorder Addiction
Compound Psilocybin Placebo
Country Australia
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 September 2024
End date 31 December 2025
Phase Phase II
Design Blinded
Type Interventional
Generation First
Participants 88
Sex All
Age 18-
Therapy Yes

Trial Details

To explore the effectiveness of psilocybin-assisted therapy on reducing alcohol consumption in a double-blind, randomised, phase II clinical trial.

NCT Number NCT06444243

Sponsors & Collaborators

University of Sydney
The University of Sydney is Australias oldest university. At the psychopharmacology laboratory, researchers have conducted some research with psychedelics.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.